• Users Online: 719
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2016  |  Volume : 32  |  Issue : 1  |  Page : 1-6

Intravenous L-alanyl-L-glutamine: an adjuvant in the management of immunocompromised patients with invasive fungal rhinosinusitis


1 Department of Anaesthesia and Intensive Care, Faculty of Medicine, Ain Shams University, Cairo, Egypt
2 Department of Otorhinolaryngology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Correspondence Address:
Mohamed M Elsharnouby
Department of Otorhinolaryngology, Faculty of Medicine, Ain Shams University, 8 Moktar Elmasry Street, El-Golf Land, Heliopolis, Cairo
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1012-5574.175792

Rights and Permissions

Background Invasive fungal rhinosinusitis is a potentially fatal infection in immunocompromised patients. Glutamine, a conditionally essential amino acid, is an energy source for rapidly dividing cells, particularly those of the immune system. This randomized, double-blind, placebo-controlled, two-group parallel study was designed to investigate intravenous l-alanyl-l-glutamine as an immune adjuvant in the management of patients with invasive fungal rhinosinusitis. Patients and methods Fourteen patients with invasive fungal rhinosinusitis undergoing endoscopic debridement and with postoperative admission to the ICU were included in this study. Group D (n = 7) received the standard protocol therapy and l-alanyl-l-glutamine 0.5 mg/kg/day infusion postoperatively for 10 days; group C (n = 7) received only the standard protocol therapy with the same volume and rate of saline postoperatively for 10 days as well. The primary outcome measure was patient response, either cure or persistence, whereas secondary outcome included length of ICU stay, ICU survival, hospital survival, and complications. Results In group D there was significant improvement in response rate as all five patients who survived in group D had a complete cure (100%), whereas in group C among the three patients who survived only one (33%) patient was completely cured. There was significant decrease in length of ICU stay (P = 0.003) and incidence of complications (P = 0.03) in group D compared with group C. The incidence of intracranial extension, renal impairment, and septic shock as well as ICU and hospital survival, was decreased in group D compared with group C but did not reach statistical significance. Conclusion Intravenous l-alanyl-l-glutamine 0.5 mg/kg/day infusion postoperatively for 10 days in patients with invasive fungal rhinosinusitis undergoing endoscopic debridement resulted in a better response accompanied with a decrease in ICU length of stay and complication rate.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1952    
    Printed17    
    Emailed0    
    PDF Downloaded208    
    Comments [Add]    

Recommend this journal